• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    3/27/24 12:31:07 PM ET
    $AKLI
    $FRES
    $LIXT
    $MESO
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Health Care
    Get the next $AKLI alert in real time by email

    Gainers

    • Stoke Therapeutics (NASDAQ:STOK) shares increased by 46.1% to $15.03 during Wednesday's regular session. The company's market cap stands at $671.1 million. As per the press release, Q4 earnings came out 2 days ago.
    • Lixte Biotechnology (NASDAQ:LIXT) shares rose 43.68% to $3.24. The company's market cap stands at $7.2 million.
    • Nuvation Bio (NYSE:NUVB) shares moved upwards by 35.41% to $3.9. The company's market cap stands at $854.2 million.
    • Ontrak (NASDAQ:OTRK) shares moved upwards by 29.18% to $0.55. The market value of their outstanding shares is at $15.2 million.
    • PAVmed (NASDAQ:PAVM) stock increased by 25.72% to $2.59. The market value of their outstanding shares is at $20.8 million. The company's, Q4 earnings came out yesterday.
    • Nutriband (NASDAQ:NTRB) stock rose 24.33% to $3.78. The market value of their outstanding shares is at $31.9 million.

    Losers

    • Akili (NASDAQ:AKLI) stock declined by 18.8% to $0.31 during Wednesday's regular session. The company's market cap stands at $24.3 million.
    • Mesoblast (NASDAQ:MESO) shares declined by 12.85% to $3.42. The company's market cap stands at $347.5 million.
    • Salarius Pharmaceuticals (NASDAQ:SLRX) stock fell 11.19% to $0.44. The company's market cap stands at $1.7 million. As per the news, the Q4 earnings report came out 3 days ago.
    • XTL Biopharmaceuticals (NASDAQ:XTLB) shares fell 11.08% to $2.73. The market value of their outstanding shares is at $14.8 million.
    • Fresh2 Group (NASDAQ:FRES) shares declined by 10.6% to $0.57. The market value of their outstanding shares is at $13.5 million.
    • PDS Biotechnology (NASDAQ:PDSB) shares decreased by 9.94% to $4.04. The company's market cap stands at $125.5 million. As per the press release, Q4 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKLI
    $FRES
    $LIXT
    $MESO

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/24/2026$40.00Outperform
    Wolfe Research
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    Nuvation Bio Inc.
    $NUVB
    11/24/2025Buy
    Truist
    Nuvation Bio Inc.
    $NUVB
    11/19/2025$12.00Buy
    B. Riley Securities
    Nuvation Bio Inc.
    $NUVB
    9/30/2025$10.00Buy
    Jefferies
    Stoke Therapeutics Inc.
    $STOK
    7/18/2025$30.00Buy
    Jefferies
    More analyst ratings

    $AKLI
    $FRES
    $LIXT
    $MESO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

    The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timelineAdditional filings are planned for the U.K., Canada and other regions included in Eisai's licensed territories Taletrectinib is already approved in the U.S., China and Japan for advanced ROS1-positive non-small cell lung cancerTOKYO and NEW YORK, March 26, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE:NUVB, Corporate Headquarters: New York, NY, CEO: David Hung,

    3/26/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Processed 3,664 EsoGuard® tests and recognized 4Q25 revenue of $1.5 millionExpanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detectionConference call and webcast to be held today, March 26, at 8:30 AM ESTNEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full

    3/26/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

    PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter and year ended December 31, 2025, and will provide a clinical programs and corporate update, on Monday, March 30, 2026 at 8:00 am Eastern Time. Conference Call DetailsDate: March 30, 2026Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)Conference I.D.: 13759288Webcast: Click HereCallMe™: Click H

    3/24/26 4:05:00 PM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $FRES
    $LIXT
    $MESO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Allan Jonathan

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    3/24/26 4:19:20 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider George Gregory

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/23/26 8:00:19 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Segal Niv

    3 - XTL BIOPHARMACEUTICALS LTD (0001023549) (Issuer)

    3/23/26 4:01:12 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $FRES
    $LIXT
    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Stoke Therapeutics with a new price target

    Wolfe Research initiated coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $40.00

    2/24/26 7:56:29 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets resumed coverage on Stoke Therapeutics with a new price target

    Chardan Capital Markets resumed coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $35.00

    1/5/26 9:19:09 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $FRES
    $LIXT
    $MESO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hanish Arnold C bought $3,740 worth of shares (5,000 units at $0.75) (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/24/25 5:08:13 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exec VP Finance, CFO Rosenblum Mark J bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 11,299% to 20,177 units (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/20/25 4:42:09 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:15 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $FRES
    $LIXT
    $MESO
    SEC Filings

    View All

    PAVmed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - PAVmed Inc. (0001624326) (Filer)

    3/27/26 5:15:28 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by PAVmed Inc.

    10-K - PAVmed Inc. (0001624326) (Filer)

    3/27/26 5:08:04 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Stoke Therapeutics Inc.

    8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)

    3/27/26 4:30:26 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $FRES
    $LIXT
    $MESO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

    SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

    11/14/24 4:38:31 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $FRES
    $LIXT
    $MESO
    Financials

    Live finance-specific insights

    View All

    Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Processed 3,664 EsoGuard® tests and recognized 4Q25 revenue of $1.5 millionExpanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detectionConference call and webcast to be held today, March 26, at 8:30 AM ESTNEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full

    3/26/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

    PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter and year ended December 31, 2025, and will provide a clinical programs and corporate update, on Monday, March 30, 2026 at 8:00 am Eastern Time. Conference Call DetailsDate: March 30, 2026Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)Conference I.D.: 13759288Webcast: Click HereCallMe™: Click H

    3/24/26 4:05:00 PM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r

    3/16/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $AKLI
    $FRES
    $LIXT
    $MESO
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care